About this episode

The episode discusses the evolution and importance of companion diagnostics in modern cancer care with insights from Agilent's leaders.

For years, precision oncology has largely been discussed through the lens of breakthrough drugs. But there’s another story running underneath modern cancer care: the quiet rise of companion diagnostics. These tests are increasingly deciding who receives those therapies in the first place. In many cases, the real bottleneck is no longer discovering a drug target. It’s building a reliable system for identifying the right patient at the right moment in the disease. That challenge sits at the center of this conversation with Rita Shaknovich, Chief Medical Officer for Life Sciences and Diagnostis, and Karina Kulangara, Associate Vice President of R&D in Companion Diagnostics at Agilent Technologies . Agilent has always had a major role in this field. Rita and Karina explain how companion diagnostics evolved from the original Herceptin test into a vision for a much broader ecosystem spanning pathology, automation, regulation, and global clinical deployment. We dive into Agilent’s recent FDA approval expanding PD-L1 IHC 22C3 PharmDx into ovarian cancer, a development both guests describe as particularly meaningful given the historically poor outcomes associated with the disease. As…

More episodes of Mendelspod Podcast

• Mapping the Multi-Omic Era with Eric Green of Illumina · May 28, 2026 · 44 min
• Inside Proteomics at Thermo Fisher with Yan Zhang · May 21, 2026 · 5 min
• Separating Epigenetic Signals Improves Early Cancer Detection with Rob Osborne, Biomodal · May 19, 2026 · 23 min
• Digital Controls for Cancer Drug Trials? Irina Babina, Concr · May 15, 2026 · 4 min

Explore listener stats, chart rankings, contacts and more on the Mendelspod Podcast podcast page.